Triclabendazole Treatment Failure for Fasciola hepatica Infection among Preschool and School-Age Children, Cusco, Peru1

Emerg Infect Dis. 2021 Jul;27(7):1850-1857. doi: 10.3201/eid2707.203900.

Abstract

We conducted a retrospective cohort study of children who had chronic fascioliasis in the highlands of Peru to determine triclabendazole treatment efficacy. Children passing Fasciola eggs in stool were offered directly observed triclabendazole treatment (>1 doses of 10 mg/kg). Parasitologic cure was evaluated by using microscopy of stool 1-4 months after each treatment. A total of 146 children who had chronic fascioliasis participated in the study; 53% were female, and the mean ± SD age was 10.4 ± 3.1 years. After the first treatment, 55% of the children achieved parasitologic cure. Cure rates decreased after the second (38%), third (30%), and fourth (23%) treatments; 17 children (11.6%) did not achieve cure after 4 treatments. Higher baseline egg counts and lower socioeconomic status were associated with triclabendazole treatment failure. Decreased triclabendazole efficacy in disease-endemic communities threatens control efforts. Further research on triclabendazole resistance and new drugs to overcome it are urgently needed.

Keywords: Cusco; Fasciola hepatica; Peru; antimicrobial resistance; drug resistance; efficacy; fascioliasis; infection; liver fluke; parasites; preschool children; school-age children; treatment failure; trematode; triclabendazole.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Animals
  • Anthelmintics* / therapeutic use
  • Child
  • Child, Preschool
  • Fasciola hepatica*
  • Fascioliasis*
  • Feces
  • Female
  • Humans
  • Peru
  • Retrospective Studies
  • Schools
  • Treatment Failure
  • Triclabendazole / therapeutic use

Substances

  • Anthelmintics
  • Triclabendazole